25 results on '"Mangat, Pam K."'
Search Results
2. Palbociclib in Patients With Soft Tissue Sarcoma With CDK4 Amplifications: Results From the Targeted Agent and Profiling Utilization Registry Study.
- Author
-
Schuetze, Scott, Rothe, Michael, Mangat, Pam K., Garrett-Mayer, Elizabeth, Meric-Bernstam, Funda, Calfa, Carmen J., Farrington, Laura Catherine, Livingston, Michael B., Wentzel, Kristopher, Behl, Deepti, Kier, Yelena, Marr, Alissa S., von Mehren, Margaret, Press, Joshua Z., Thota, Ramya, Grantham, Gina N., Gregory, Abigail, Hinshaw, Dominique C., Halabi, Susan, and Schilsky, Richard L.
- Subjects
SARCOMA ,CYCLIN-dependent kinases ,CANCER patients ,ALANINE aminotransferase ,OVERALL survival - Abstract
PURPOSE: Targeted Agent and Profiling Utilization Registry (TAPUR) is a phase II basket trial evaluating the antitumor activity of commercially available targeted agents in patients with advanced cancer and genomic alterations known to be drug targets. Results of a cohort of patients with soft tissue sarcoma with cyclin-dependent kinase 4 (CDK4) amplification treated with palbociclib are reported. METHODS: Eligible patients had measurable disease, Eastern Cooperative Oncology Group performance status 0 to 2, adequate organ function, and no standard treatment options. The primary end point was disease control (DC), defined as objective response (OR) or stable disease (SD) of at least 16+ weeks duration (SD16+) according to RECIST v1.1. The DC rate was estimated with a 90% CI. Secondary end points included OR, progression-free survival (PFS), overall survival (OS), duration of response, duration of SD, and safety. RESULTS: Forty-two patients with CDK4 amplification were enrolled. One patient was not evaluable for efficacy. One patient with partial response and 18 with SD16+ were observed for DC and OR rates of 46% (90% CI, 36 to 100) and 2% (95% CI, <1 to 13), respectively. Median PFS was 16 weeks (95% CI, 9 to 28) and median OS was 69 weeks (95% CI, 31 to 111) for evaluable patients. Twenty patients had at least one grade 3 to 4 adverse event (AE) at least possibly related to palbociclib, including alanine aminotransferase increase, anemia, fatigue, hypophosphatemia, leukopenia, neutropenia, and thrombocytopenia. No serious AEs were reported. CONCLUSION: Palbociclib met prespecified criteria to declare a signal of antitumor activity in patients with sarcoma and CDK4 amplification. Palbociclib met @ASCO #TAPUR criteria to declare antitumor activity in patients with CDK4-amplified liposarcoma. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Talazoparib in Patients With Solid Tumors With BRCA1 / 2 Mutation: Results From the Targeted Agent and Profiling Utilization Registry Study.
- Author
-
Srkalovic, Gordan, Rothe, Michael, Mangat, Pam K., Garrett-Mayer, Elizabeth, Ahn, Eugene R., Brouse, Gregory, Chan, John, Mehmi, Inderjit, Khalil, Maya, Duvivier, Herbert L., Gaba, Anu, Leuva, Harshraj, Thota, Ramya, Yost, Kathleen J., Grantham, Gina N., Gregory, Abigail, Hinshaw, Dominique C., Halabi, Susan, and Schilsky, Richard L.
- Subjects
POLY(ADP-ribose) polymerase ,EPIDERMAL growth factor receptors ,CANCER patients ,NON-small-cell lung carcinoma ,BRCA genes ,HORMONE receptor positive breast cancer ,SKIN cancer - Abstract
PURPOSE: The Targeted Agent and Profiling Utilization Registry Study is a phase II basket trial evaluating the antitumor activity of commercially available targeted agents in patients with advanced cancer and genomic alterations known to be drug targets. Results of a cohort of patients with various solid tumors with germline or somatic BRCA1/2 mutations treated with talazoparib are reported. METHODS: Eligible patients had advanced solid tumors, measurable disease (RECIST), Eastern Cooperative Oncology Group performance status 0-2, adequate organ function, and no standard treatment options. Patients with germline BRCA -mutated human epidermal growth factor receptor 2–negative locally advanced or metastatic breast cancer were not eligible for this study. Primary end point was disease control (DC) determined by investigator assessment of objective response (OR) or stable disease (SD) of at least 16 weeks duration (SD16+). The results were evaluated on the basis of a one-sided exact binomial test with a null DC rate of 15% versus 35% (power = 0.82; α =.10). Secondary end points were OR, progression-free survival, overall survival, duration of response, duration of SD, and safety. RESULTS: Twenty-eight patients (20 cancer types) with BRCA1/2 mutations were enrolled from December 2019 to September 2021 and collapsed into a single histology pooled cohort for analysis. All patients were evaluable for efficacy. One complete response, nine partial response, and six SD16+ were observed for DC and OR rates of 57% (one-sided 90% CI, 43 to 100) and 36% (95% CI, 19 to 56), respectively. The null hypothesis of a 15% DC rate was rejected (P <.001). Patients with OR had the following tumor types: breast (2), nonmelanoma skin, mesothelioma, stomach, uterus, non–small cell lung cancer, ovary, hepatocellular carcinoma, and pancreas. Thirteen patients had at least one grade 3-5 adverse event (AE) or serious AE at least possibly related to talazoparib. All were consistent with the drug label except bilirubin increase and hyponatremia (both grade 3 AEs). CONCLUSION: Talazoparib demonstrated antitumor activity in patients with advanced solid tumors and BRCA1/2 mutations, including cancer types for which poly ADP-ribose polymerase inhibitors are not yet US Food and Drug Administration–approved. Talazoparib showed activity in patients with BRCA-mutated tumors for which PARP inhibitors are not yet FDA-approved. @ASCO #TAPUR [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Sunitinib in Patients with Metastatic Colorectal Cancer (mCRC) with FLT-3 Amplification: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
- Author
-
Al Baghdadi, Tareq, Garrett-Mayer, Elizabeth, Halabi, Susan, Mangat, Pam K., Rich, Patricia, Ahn, Eugene R., Chai, Seungjean, Rygiel, Andrew L., Osayameh, Olufunlayo, Antonelli, Kaitlyn R., Islam, Samiha, Bruinooge, Suanna S., and Schilsky, Richard L.
- Published
- 2020
- Full Text
- View/download PDF
5. Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
- Author
-
Fisher, Julie G., Tait, David, Garrett-Mayer, Elizabeth, Halabi, Susan, Mangat, Pam K., Schink, Julian C., Alvarez, Ricardo H., Veljovich, Dan, Cannon, Timothy L., Crilley, Pamela A., Pollock, Theodore, Calfa, Carmen J., Al Baghdadi, Tareq, Thota, Ramya, Fleming, Nicole, Cotta, Jared A., Rygiel, Andrew L., Warren, Sasha L., and Schilsky, Richard L.
- Published
- 2020
- Full Text
- View/download PDF
6. Cobimetinib Plus Vemurafenib in Patients With Colorectal Cancer With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
- Author
-
Klute, Kelsey A., Rothe, Michael, Garrett-Mayer, Elizabeth, Mangat, Pam K., Nazemzadeh, Reza, Yost, Kathleen J., Duvivier, Herbert L., Ahn, Eugene R., Cannon, Timothy L., Alese, Olatunji B., Krauss, John C., Thota, Ramya, Calfa, Carmen J., Denlinger, Crystal S., OʼLone, Raegan, Halabi, Susan, Grantham, Gina N., and Schilsky, Richard L.
- Published
- 2022
- Full Text
- View/download PDF
7. Pertuzumab Plus Trastuzumab in Patients With Colorectal Cancer With ERBB2 Amplification or ERBB2/3 Mutations: Results From the TAPUR Study
- Author
-
Gupta, Ranju, Meric-Bernstam, Funda, Rothe, Michael, Garrett-Mayer, Elizabeth, Mangat, Pam K., DʼAndre, Stacy, Ahn, Eugene R., OʼLone, Raegan, Halabi, Susan, Grantham, Gina N., and Schilsky, Richard L.
- Published
- 2022
- Full Text
- View/download PDF
8. Sunitinib in Patients With Breast Cancer With FGFR1 or FGFR2 Amplifications or Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study.
- Author
-
Calfa, Carmen J., Rothe, Michael, Mangat, Pam K., Garrett-Mayer, Elizabeth, Ahn, Eugene R., Burness, Monika L., Gogineni, Keerthi, Rohatgi, Nitin, Al Baghdadi, Tareq, Conlin, Alison, Gaba, Anu, Hamid, Omid, Krishnamurthy, Jairam, Gavini, Naga Jyothi, Gold, Philip J., Rodon, Jordi, Rueter, Jens, Thota, Ramya, Grantham, Gina N., and Hinshaw, Dominique C.
- Subjects
SUNITINIB ,CANCER patients ,BREAST cancer ,METASTATIC breast cancer ,DRUG target - Abstract
PURPOSE: The Targeted Agent and Profiling Utilization Registry Study is a phase II basket trial evaluating the antitumor activity of commercially available targeted agents in patients with advanced cancer and genomic alterations known to be drug targets. Results from cohorts of patients with metastatic breast cancer (BC) with FGFR1 and FGFR2 alterations treated with sunitinib are reported. METHODS: Eligible patients had measurable disease, Eastern Cooperative Oncology Group performance status 0-2, adequate organ function, and no standard treatment options. Simon's two-stage design was used with a primary end point of disease control (DC), defined as objective response (OR) or stable disease of at least 16 weeks duration (SD16+) according to RECIST v1.1. Secondary end points included OR, progression-free survival, overall survival, duration of response, duration of stable disease, and safety. RESULTS: Forty patients with BC with FGFR1 (N = 30; amplification only n = 26, mutation only n = 1, both n = 3) or FGFR2 (N = 10; amplification only n = 2, mutation only n = 6, both n = 2) alterations were enrolled. Three patients in the FGFR1 cohort were not evaluable for efficacy; all patients in the FGFR2 cohort were evaluable. For the FGFR1 cohort, two patients with partial response and four with SD16+ were observed for DC and OR rates of 27% (90% CI, 13 to 100) and 7% (95% CI, 1 to 24), respectively. The null hypothesis of 15% DC rate was not rejected (P =.169). No patients achieved DC in the FGFR2 cohort (P = 1.00). Thirteen of the 40 total patients across both cohorts had at least one grade 3-4 adverse event or serious adverse event at least possibly related to sunitinib. CONCLUSION: Sunitinib did not meet prespecified criteria to declare a signal of antitumor activity in patients with BC with either FGFR1 or FGFR2 alterations. Other treatments and clinical trials should be considered for these patient populations. Sunitinib did not demonstrate antitumor activity in patients with FGFR1-/2-amplified or -mutated breast cancer. @ASCO #TAPUR [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
9. Abemaciclib in patients (pts) with esophageal cancer (EC) with CDKN2A loss or mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
- Author
-
Al Baghdadi, Tareq, Rothe, Michael, Mangat, Pam K., Garrett-Mayer, Elizabeth, Yost, Kathleen J, Chiu, Vi Kien, Duvivier, Herbert Leon, McKean, Meredith, Rueter, Jens, Taylor, Mark A., Grantham, Gina N., Gregory, Abby, Hinshaw, Dominique C., Halabi, Susan, and Schilsky, Richard L.
- Published
- 2024
- Full Text
- View/download PDF
10. Talazoparib (Tala) in patients (pts) with colorectal cancer (CRC) with BRCA1/2 mutations (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
- Author
-
Yost, Kathleen J, Rothe, Michael, Mangat, Pam K., Garrett-Mayer, Elizabeth, Duvivier, Herbert Leon, Ahn, Eugene R., Cannon, Timothy Lewis, Chiu, Vi Kien, Khalil, Maged F., Kim, Brian, Prinz, Allison Marie, Grantham, Gina N., Gregory, Abby, Hinshaw, Dominique C., Halabi, Susan, and Schilsky, Richard L.
- Published
- 2024
- Full Text
- View/download PDF
11. Cobimetinib Plus Vemurafenib in Patients With Solid Tumors With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study.
- Author
-
Meric-Bernstam, Funda, Rothe, Michael, Mangat, Pam K., Garrett-Mayer, Elizabeth, Gutierrez, Rodolfo, Ahn, Eugene R., Cannon, Timothy L., Powell, Steven, Krauss, John C., Reynolds, Christopher M., von Mehren, Margaret, Behl, Deepti, Calfa, Carmen J., Duvivier, Herbert L., Kaplan, Henry G., Livingston, Michael B., Sharma, Manish R., Urba, Walter J., Grantham, Gina N., and Hinshaw, Dominique C.
- Subjects
VEMURAFENIB ,BRAF genes ,CANCER patients ,PATIENT experience ,ANTINEOPLASTIC agents ,OVARIAN cancer - Abstract
PURPOSE: The Targeted Agent and Profiling Utilization Registry Study is a phase II basket study evaluating antitumor activity of commercially available targeted agents in patients with advanced cancers with genomic alterations known to be drug targets. The results in a cohort of patients with solid tumors with BRAF mutations treated with cobimetinib plus vemurafenib are reported. METHODS: Eligible patients had measurable disease (RECIST v.1.1), Eastern Cooperative Oncology Group performance status 0-2, adequate organ function, and no standard treatment options. The primary end point was disease control (DC), defined as complete response (CR) or partial response (PR) or stable disease of at least 16-weeks duration (SD16+). Low-accruing histology-specific cohorts with BRAF mutations treated with cobimetinib plus vemurafenib were collapsed into a single histology-pooled cohort for this analysis. The results were evaluated on the basis of a one-sided exact binomial test with a null DC rate of 15% versus 35% (power,.82; α,.10). The secondary end points were objective response (OR), progression-free survival, overall survival, duration of response, duration of stable disease, and safety. RESULTS: Thirty-one patients with solid tumors with BRAF mutations were enrolled. Twenty-eight patients were evaluable for efficacy. Patients had tumors with BRAF V600E (n = 26), K601E (n = 2), or other (n = 3) mutations. Two patients with CR (breast and ovarian cancers; V600E), 14 with PR (13 V600E, one N581I), and three with SD16+ (two V600E, one T599_V600insT) were observed with a DC rate of 68% (P <.0001; one-sided 90% CI, 54 to 100) and an OR rate of 57% (95% CI, 37 to 76). Nineteen patients experienced ≥one drug-related grade 3-5 adverse event or serious adverse event including one death attributed to treatment-related kidney injury. CONCLUSION: Cobimetinib plus vemurafenib showed antitumor activity in patients with advanced solid tumors with BRAF V600E mutations; additional study is warranted to confirm the antitumor activity in tumors with non-V600E BRAF mutations. @ASCO #TAPUR results build upon efficacy of BRAF + MEK inhibitors in patients with advanced solid tumors and BRAF V600E mutations [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
12. The Targeted Agent and Profiling Utilization Registry Study: A pragmatic clinical trial.
- Author
-
Mangat, Pam K, Garrett-Mayer, Elizabeth, Perez, Jacqueline K, and Schilsky, Richard L
- Subjects
THERAPEUTIC use of antineoplastic agents ,SPECIALTY hospitals ,CLINICAL trials ,COMMUNITY health services ,GENETIC testing ,INDIVIDUALIZED medicine ,EVIDENCE-based medicine ,CANCER treatment ,CONCEPTUAL structures ,COMPARATIVE studies ,DESCRIPTIVE statistics ,RESEARCH funding ,TUMORS ,OFF-label use (Drugs) - Abstract
The conceptual framework of pragmatism in clinical trials is explored using the American Society of Clinical Oncology's pragmatic, non-randomized, phase II, multi-center basket clinical trial, the Targeted Agent and Profiling Utilization Registry Study (NCT02693535) as a model. The Targeted Agent and Profiling Utilization Registry Study aims to identify signals of drug activity when Food and Drug Administration approved drugs are matched to pre-specified genomic targets in patients with advanced cancer outside of their approved indication(s). The objectives of the study are to generate evidence of potential signals of activity in targeted therapies prescribed in an off-label setting as well as to expose and educate community cancer centers to genomic testing and precision medicine through the study protocol. The principles of pragmatic trial design can be applied across a broad spectrum of evidence-generation strategies, from explanatory trials to real-world evidence studies, and are briefly discussed. American Society of Clinical Oncology's Targeted Agent and Profiling Utilization Registry Study falls closer to the pragmatic end of this spectrum as it seeks to assess the efficacy of Food and Drug Administration approved drugs used outside their approved indications under usual care conditions, yielding results generalizable to the population that would likely receive the intervention in practice, while still adhering to rigorous data quality standards. The Targeted Agent and Profiling Utilization Registry Study's pragmatic objectives, characteristics, strengths, and limitations in its implementation are discussed and demonstrate that a large, multi-center, precision medicine basket trial can be mounted in the context of community practice and can generate clinically useful information with minimal burden to patients and clinical trial sites. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
13. Pembrolizumab in Patients With Tumors With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry Study.
- Author
-
Duvivier, Herbert L., Rothe, Michael, Mangat, Pam K., Garrett-Mayer, Elizabeth, Ahn, Eugene R., Al Baghdadi, Tareq, Alva, Ajjai S., Dublis, Stephanie A., Cannon, Timothy L., Calfa, Carmen J., Li, Rui, Behl, Deepti, Chiu, Vi K., Gold, Philip J., Marr, Alissa S., Mileham, Kathryn F., Powell, Steven Francis, Rodon, Jordi, Thota, Ramya, and Grantham, Gina N.
- Published
- 2023
- Full Text
- View/download PDF
14. Nivolumab Plus Ipilimumab in Patients With Solid Tumors With ATM Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
- Author
-
Rohatgi, Nitin, Rothe, Michael, Mangat, Pam K., Garrett-Mayer, Elizabeth, Meric-Bernstam, Funda, Pisick, Evan, Alese, Olatunji B., Reynolds, Christopher M., Thota, Ramya, Vaccaro, Gina M., von Mehren, Margaret, Arend, Rebecca C., Chiu, Vi K., Duvivier, Herbert L., Gold, Philip J., Hack, Keely, Marr, Alissa S., Winer, Arthur, Grantham, Gina N., and Hinshaw, Dominique C.
- Subjects
NIVOLUMAB ,IPILIMUMAB ,CANCER patients ,AUTOMATED teller machines ,DRUG target - Abstract
PURPOSE: The Targeted Agent and Profiling Utilization Registry Study is a phase II basket study evaluating the antitumor activity of commercially available targeted agents in patients with advanced cancers with genomic alterations known to be drug targets. Results of a cohort of patients with solid tumors with ATM mutations treated with nivolumab plus ipilimumab are reported. METHODS: Eligible patients had measurable disease (RECIST v.1.1), Eastern Cooperative Oncology Group performance status 0-2, adequate organ function, and no standard treatment options. Primary end point was disease control (DC), defined as complete (CR) or partial (PR) response or stable disease (SD) of at least 16 weeks duration (SD16+). Low-accruing histology-specific cohorts with ATM mutations treated with nivolumab plus ipilimumab were collapsed into a single histology-pooled cohort for this analysis. The results were evaluated based on a one-sided exact binomial test with a null DC rate of 15% versus 35% (power =.84; α =.10). Secondary end points were objective response (OR), progression-free survival, overall survival, duration of response, duration of SD, and safety. RESULTS: Twenty-nine patients with 10 tumor types with ATM mutations were enrolled from January 2018 to May 2020. One patient was not evaluable for efficacy. One CR, three PR, and three SD16+ were observed for DC and OR rates of 24% (P =.13; one-sided 90% CI: 14 to 100) and 14% (95% CI: 4 to 32), respectively. The null hypothesis of 15% DC rate was not rejected. Eleven patients had one treatment-related grade 3 adverse event (AE) or serious AE. There were two treatment-related patient deaths including immune-related encephalitis and respiratory failure. CONCLUSION: Nivolumab plus ipilimumab did not meet prespecified criteria to declare a signal of activity in patients with solid tumors with ATM mutations. Nivolumab + ipilimumab did not meet @ASCO #TAPUR criteria to declare antitumor activity in patients w/ ATM-mutated solid tumors. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
15. Pertuzumab Plus Trastuzumab in Patients With Lung Cancer With ERBB2 Mutation or Amplification: Results From the Targeted Agent and Profiling Utilization Registry Study.
- Author
-
Ganti, Apar K., Rothe, Michael, Mangat, Pam K., Garrett-Mayer, Elizabeth, Dib, Elie G., Duvivier, Herbert L., Ahn, Eugene R., Behl, Deepti, Borghaei, Hossein, Balmanoukian, Ani S., Gaba, Anu, Li, Rui, Osei-Boateng, Kwabena, Thota, Ramya, Grantham, Gina N., Gregory, Abigail, Halabi, Susan, and Schilsky, Richard L.
- Subjects
CANCER patients ,LUNG cancer ,TRASTUZUMAB ,INSERTION mutation ,NON-small-cell lung carcinoma - Abstract
PURPOSE: The Targeted Agent and Profiling Utilization Registry Study is a pragmatic basket trial evaluating antitumor activity of commercially available targeted agents in patients with advanced cancers harboring potentially actionable genomic alterations. Data from a cohort of patients with lung cancer and ERBB2 mutation or amplification treated with pertuzumab plus trastuzumab (P + T) are reported. METHODS: Eligible patients had advanced lung cancer of any histology, no standard treatment options, measurable disease (RECIST v1.1), Eastern Cooperative Oncology Group performance status 0-2, adequate organ function, and tumors with ERBB2 mutation or amplification. Simon's two-stage design was used with a primary end point of disease control (DC), defined as objective response (OR) per RECIST v. 1.1 or stable disease (SD) of at least 16 weeks duration (SD16+). Secondary end points included safety, duration of response, duration of SD, progression-free survival, and overall survival. RESULTS: Twenty-eight patients with lung cancer (27 non–small-cell, 1 small-cell) and ERBB2 mutation (n = 15), ERBB2 amplification (n = 12), or both (n = 1) were enrolled from November 2016 to July 2020. All patients were evaluable for efficacy and toxicity. Three patients with partial response (two ERBB2 mutation; one both mutation and amplification) and seven patients with SD16+ (five ERBB2 mutation; two amplification) were observed for a DC rate of 37% (95% CI, 21 to 50; P =.005) and OR rate of 11% (95% CI, 2 to 28). Five patients had one or more grade 3 or 4 adverse or serious adverse events at least possibly related to P + T. CONCLUSION: Combination P + T showed evidence of antitumor activity in heavily pretreated patients with non–small-cell lung cancer and ERBB2 mutation or amplification, particularly those with ERBB2 exon 20 insertion mutations. Pertuzumab + trastuzumab had antitumor activity in pretreated patients with ERBB2-mutated NSCLC @ASCO #TAPUR. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
16. Pertuzumab Plus Trastuzumab in Patients With Endometrial Cancer With ERBB2/3 Amplification, Overexpression, or Mutation: Results From the TAPUR Study.
- Author
-
Ahn, Eugene R., Rothe, Michael, Mangat, Pam K., Garrett-Mayer, Elizabeth, Ali-Ahmad, Hussein M., Chan, John, Maitland, Michael L., Patel, Sapna R., Reese, Zachary, Balmanoukian, Ani S., Drescher, Charles W., Li, Rui, Tsimberidou, Apostolia M., Leath III, Charles A., O'Lone, Raegan, Grantham, Gina N., Halabi, Susan, and Schilsky, Richard L.
- Subjects
ENDOMETRIAL cancer ,TRASTUZUMAB ,CANCER patients ,GENETIC overexpression ,MUSCLE weakness - Abstract
PURPOSE: The TAPUR Study is a pragmatic basket trial evaluating antitumor activity of commercially available targeted agents in patients with advanced cancers harboring potentially actionable genomic alterations. Data from a cohort of patients with endometrial cancer (EC) with ERBB2 or ERBB3 (ERBB2/3) amplification, overexpression, or mutation treated with pertuzumab plus trastuzumab (P + T) are reported. METHODS: Eligible patients had advanced EC, no standard treatment options, measurable disease (RECIST v1.1), Eastern Cooperative Oncology Group performance status 0-2, adequate organ function, and tumors with ERBB2/3 amplification, overexpression, or mutation. Simon's two-stage design was used with a primary end point of disease control (DC), defined as objective response (OR) or stable disease (SD) of at least 16 weeks (SD16+) duration. Secondary end points include safety, duration of response, duration of SD, progression-free survival (PFS), and overall survival (OS). RESULTS: Twenty-eight patients were enrolled from March 2017 to November 2019; all patients were evaluable for efficacy and toxicity. Seventeen patients had tumors with ERBB2/3 amplification and/or overexpression, eight with both ERBB2 amplification and ERBB2/3 mutations, and three with only ERBB2 mutations. Ten patients had DC (two partial response and eight SD16+); all 10 had ERBB2 amplification, and 6 of the 10 patients with DC had >1 ERBB2/3 alteration. DC and OR rates were 37% (95% CI, 21 to 50) and 7% (95% CI, 1 to 24), respectively; the median PFS and median OS were 16 weeks (95% CI, 10-28) and 61 weeks (95% CI, 24-105), respectively. One patient experienced a grade 3 serious adverse event (muscle weakness) at least possibly related to P + T. CONCLUSION: P + T has antitumor activity in heavily pretreated patients with EC with ERBB2 amplification and warrants additional study. Pertuzumab + trastuzumab had antitumor activity in patients with endometrial cancer with ERBB2/3 alterations @ASCO #TAPUR. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
17. Olaparib in Patients With Metastatic Prostate Cancer With BRCA1 / 2 Mutation: Results From the TAPUR Study.
- Author
-
Yang, Eddy S., Halabi, Susan, Rothe, Michael, Garrett-Mayer, Elizabeth, Mangat, Pam K., Pisick, Evan, Dib, Elie, Burgess, Earle F., Zakem, Michael, Rohatgi, Nitin, Bilen, Mehmet A., O'Lone, Raegan, Grantham, Gina N., and Schilsky, Richard L.
- Subjects
PROSTATE cancer patients ,PROSTATE cancer ,BRCA genes ,OLAPARIB ,CANCER patients ,PROGRESSION-free survival - Abstract
PURPOSE: The TAPUR Study is a phase II basket trial that aims to evaluate activity of approved targeted agents in patients with advanced cancers with potentially actionable genomic variants. Data from a cohort of patients with metastatic castrate-resistant prostate cancer (mCRPC) and BRCA1 / 2 mutations treated with olaparib are reported. METHODS: Eligible patients with measurable mCRPC were matched to treatment according to protocol-specified genomic matching rules. Patients had no remaining standard treatment options, Eastern Cooperative Oncology Group performance status 0-2, and adequate organ function. Simon's two-stage design was used with a primary end point of disease control, defined as objective response or stable disease of at least 16-week duration. Secondary end points include radiographic progression-free survival, overall survival, duration of response, duration of stable disease, and safety. RESULTS: Thirty patients with mCRPC with BRCA1 / 2 mutations were treated with olaparib. The disease control rate was 69% (95% CI, 51 to 81), and the objective response rate was 58% (95% CI, 37 to 77). The median radiographic progression-free survival and the median overall survival were 38.4 (95% CI, 16.3 to 52.1) weeks and 76.4 (95% CI, 49.3 to 106.0) weeks, respectively. Six of 30 (20%) patients experienced grade 3-4 adverse or serious adverse events including anemia, aspiration, decreased WBC count, and fatigue. CONCLUSION: Olaparib has antitumor activity in patients with mCRPC with BRCA1 / 2 mutations and warrants further study to determine how to best integrate it into the standard treatment of patients with BRCA1 / 2 -mutated prostate cancer. Olaparib showed a positive signal of activity in real-world patients w/prostate cancer w/BRCA1 or BRCA2 mutations @ASCO #TAPUR. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
18. Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
- Author
-
Alva, Ajjai S, Mangat, Pam K, Garrett-Mayer, Elizabeth, Halabi, Susan, Hansra, Damien, Calfa, Carmen J, Khalil, Maged F, Ahn, Eugene R, Cannon, Timothy L, Crilley, Pamela, Fisher, Julie G, Haslem, Derrick S, Shrestha, Sagun, Antonelli, Kaitlyn R, Butler, Nicole L, Warren, Sasha L, Rygiel, Andrew L, Ranasinghe, Shamika, Bruinooge, Suanna S, and Schilsky, Richard L
- Published
- 2021
- Full Text
- View/download PDF
19. Palbociclib in Patients With Non–Small-Cell Lung Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study.
- Author
-
Ahn, Eugene R., Mangat, Pam K., Garrett-Mayer, Elizabeth, Halabi, Susan, Dib, Elie G., Haggstrom, Daniel E., Alguire, Kathryn B., Calfa, Carmen J., Cannon, Timothy L., Crilley, Pamela A., Gaba, Anu G., Marr, Alissa S., Sangal, Ashish, Thota, Ramya, Antonelli, Kaitlyn R., Islam, Samiha, Rygiel, Andrew L., Bruinooge, Suanna S., and Schilsky, Richard L.
- Subjects
- *
NON-small-cell lung carcinoma , *FEBRILE neutropenia , *PROGRESSION-free survival - Abstract
PURPOSE: The Targeted Agent and Profiling Utilization Registry (TAPUR) Study is a phase II pragmatic basket trial evaluating antitumor activity of commercially available targeted agents in patients with advanced cancer with genomic alterations known to be drug targets. Results in a cohort of patients with non–small-cell lung cancer (NSCLC) with CDKN2A alterations treated with palbociclib are reported. METHODS: Eligible patients were ≥ 18 years old with advanced NSCLC, no remaining standard treatment options, measurable disease, Eastern Cooperative Oncology Group performance status of 0 to 2, and adequate organ function. Patients with NSCLC with CDKN2A alterations and no Rb mutations received palbociclib 125 mg orally once daily for 21 days, followed by 7 days off. Simon's two-stage design was used with a primary study end point of objective response or stable disease (SD) of at least 16 weeks in duration. Secondary end points are progression-free survival (PFS), overall survival (OS), and safety. RESULTS: Twenty-nine patients were enrolled from January 2017 to June 2018; two patients were not evaluable for response but were included in safety analyses. One patient with partial response and six patients with SD were observed, for a disease control rate of 31% (90% CI, 19% to 40%). Median PFS was 8.1 weeks (95% CI, 7.1 to 16.0 weeks), and median OS was 21.6 weeks (95% CI, 14.1 to 41.1 weeks). Eleven patients had at least 1 grade 3 or 4 adverse event (AE) or serious AE (SAE) possibly related to palbociclib (most common, cytopenias). Other AEs or SAEs possibly related to the treatment included anorexia, fatigue, febrile neutropenia, hypophosphatemia, sepsis, and vomiting. CONCLUSION: Palbociclib monotherapy demonstrated evidence of modest antitumor activity in heavily pretreated patients with NSCLC with CDKN2A alterations. Additional investigation is necessary to confirm efficacy and utility of palbociclib in this population. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
20. Palbociclib in Patients With Pancreatic and Biliary Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study.
- Author
-
Al Baghdadi, Tareq, Halabi, Susan, Garrett-Mayer, Elizabeth, Mangat, Pam K., Ahn, Eugene R., Sahai, Vaibhav, Alvarez, Ricardo H., Kim, Edward S., Yost, Kathleen J., Rygiel, Andrew Lawrence, Antonelli, Kaitlyn R., Butler, Nicole L., Bruinooge, Suanna S., and Schilsky, Richard L.
- Subjects
PANCREATIC cancer ,PROGRESSION-free survival ,TARGETED drug delivery - Abstract
PURPOSE: The Targeted Agent and Profiling Utilization Registry (TAPUR) Study identifies signals of antitumor activity of commercially available targeted agents in patients with advanced cancers that harbor genomic alterations known as drug targets. In this article, data from two cohorts of patients with pancreatic and biliary cancers with CDKN2A loss or mutation treated with palbociclib are reported. METHODS: Eligible patients age 12 years and older with advanced measurable or evaluable solid tumors are provided treatment according to protocol-specified genomic matching rules. The primary study end point is objective response or stable disease of at least 16 weeks duration. For each cohort, a Simon two-stage design was used with a futility evaluation after 10 patients. Secondary end points include safety, progression-free survival (PFS), and overall survival (OS). RESULTS: Between July 2016 and November 2017, 12 and 10 patients with pancreatic and biliary cancer, respectively, with CDKN2A loss or mutation were treated with palbociclib. Twenty evaluable patients (10 per cohort) were included in the analysis. No patients had objective response or stable disease at 16 weeks, and both cohorts were closed. Two patients, neither with response, were determined to be ineligible. All patients were evaluated for safety, PFS, and OS. A median PFS of 7.2 weeks (90% CI, 4.0 to 8.0 weeks) and median OS of 12.4 weeks (90% CI, 4.7 to 23.1 weeks) were observed in the pancreatic cohort. A median PFS of 7.3 weeks (90% CI, 3.9 to 7.9 weeks) and median OS of 11.1 weeks (90% CI, 5.1 to 14.0 weeks) were observed in the biliary cohort. No unexpected toxicities were observed. CONCLUSION: Palbociclib monotherapy does not have clinical activity in patients with advanced pancreatic or biliary cancers with CDKN2A loss or mutation. Toxicity is similar to reported experience with palbociclib in other tumor types. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
21. Rationale and Design of the Targeted Agent and Profiling Utilization Registry Study.
- Author
-
Mangat, Pam K., Halabi, Susan, Bruinooge, Suanna S., Garrett-Mayer, Elizabeth, Alva, Ajjai, Janeway, Katherine A., Stella, Philip J., Voest, Emile, Yost, Kathleen J., Perlmutter, Jane, Pinto, Navin, Kim, Edward S., and Schilsky, Richard L.
- Subjects
- *
TARGETED drug delivery , *DOSAGE forms of drugs , *CANCER treatment , *LYMPHOMAS , *ANTINEOPLASTIC agents - Abstract
Purpose: Case reports and small prospective trials suggest that administering targeted therapies to patients with advanced cancer and an identified genomic target may be associated with clinical benefit. The Targeted Agent and Profiling Utilization Registry (TAPUR) study, a phase II prospective, nonrandomized, multibasket pragmatic clinical trial, aims to identify signals of drug activity when US Food and Drug Administration–approved drugs are matched to prespecified genomic targets in patients with advanced cancer, outside of approved indications. Methods: Patients eligible to participate in TAPUR are age ≥ 12 years and have advanced measurable or evaluable solid tumors, multiple myeloma, or B-cell non-Hodgkin lymphoma. Eligible participants are matched to any of the 16 US Food and Drug Administration–approved study drugs based on protocol-specified genomic inclusion and exclusion criteria. Genomic profiling from any Clinical Laboratory Improvement Amendments–certified, College of American Pathologists–accredited laboratory is acceptable. The treating physician selects the treatment from the available study therapies or consults with the TAPUR Molecular Tumor Board. Participants are placed into multiple parallel cohorts defined by tumor type, genomic alteration, and drug. The primary study end point within each cohort is objective response or stable disease of at least 16 weeks duration. Secondary end points include safety, progression-free survival, and overall survival. Results: More than 1,000 participants have thus far been registered, and more than 800 have been treated with a TAPUR study drug. Two study cohorts have permanently closed to enrollment because of lack of antitumor activity, and 12 have expanded to the second stage of enrollment after promising preliminary activity. Conclusion: The TAPUR study will describe the efficacy and toxicity of the targeted drugs used outside of their approved indications when matched to a somatic genomic variant. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
22. Nivolumab plus ipilimumab (N+I) in patients (pts) with ovarian cancer (OC) with BRCA1/2 mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
- Author
-
Drescher, Charles, Rothe, Michael, Mangat, Pam K., Garrett-Mayer, Elizabeth, Behl, Deepti, Ahn, Eugene R, Al Baghdadi, Tareq, Naumann, R. Wendel, Bell, Maria C, Leath, Charles A., Cannon, Timothy Lewis, Alese, Olatunji B., Grantham, Gina N., Gregory, Abigail, Hinshaw, Dominique C., Halabi, Susan, and Schilsky, Richard L.
- Published
- 2023
- Full Text
- View/download PDF
23. Talazoparib (Tala) in patients (pts) with solid tumors with BRCA1/2 mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
- Author
-
Srkalovic, Gordan, Rothe, Michael, Mangat, Pam K., Garrett-Mayer, Elizabeth, Ahn, Eugene R, Brouse, Gregory, Chan, John K, Mehmi, Inderjit, Khalil, Maya, Duvivier, Herbert Leon, Gaba, Anu G., Leuva, Harshraj, Thota, Ramya, Yost, Kathleen J, Grantham, Gina N., Gregory, Abigail, Hinshaw, Dominique C., Halabi, Susan, and Schilsky, Richard L.
- Published
- 2023
- Full Text
- View/download PDF
24. Olaparib (O) in patients (pts) with colorectal cancer (CRC) with ATM mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
- Author
-
Behl, Deepti, Rothe, Michael, Mangat, Pam K., Garrett-Mayer, Elizabeth, Farrington, Laura Catherine, Crysler, Oxana V., Dib, Elie G., Duvivier, Herbert Leon, Hall, Michael J., Salmon, John Stuart, Alese, Olatunji B., Marr, Alissa S., Ngirailemesang, Isa, Polavaram, Latha, Thota, Ramya, Yang, Eddy Shih-Hsin, O'Lone, Raegan, Grantham, Gina N., Halabi, Susan, and Schilsky, Richard L.
- Published
- 2023
- Full Text
- View/download PDF
25. Regorafenib in Patients With Solid Tumors With BRAF Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
- Author
-
Sahai V, Rothe M, Mangat PK, Garrett-Mayer E, Suhag V, Dib EG, Mehmi I, Kadakia KC, Pisick E, Duvivier HL, Le P, Li R, Michelin DP, Wilcox RE, Grantham GN, Hinshaw DC, Gregory A, Halabi S, and Schilsky RL
- Subjects
- Humans, Proto-Oncogene Proteins B-raf genetics, Pyridines adverse effects, Antineoplastic Agents adverse effects, Neoplasms drug therapy, Neoplasms genetics, Phenylurea Compounds
- Abstract
Purpose: Targeted Agent and Profiling Utilization Registry is a phase II basket trial evaluating the antitumor activity of commercially available targeted agents in patients with advanced cancer with genomic alterations known to be drug targets. Results of a cohort of patients with solid tumors with BRAF alterations treated with regorafenib are reported., Methods: Eligible patients had measurable disease (RECIST v.1.1), Eastern Cooperative Oncology Group performance status 0-1, adequate organ function, and no standard treatment options. The primary end point was disease control (DC), defined as investigator assessment of patients with complete or partial response (PR) or stable disease of at least 16-weeks duration (SD16+). Low accruing histology-specific cohorts with BRAF alterations treated with regorafenib were collapsed into a single histology-pooled cohort for this analysis. The results were evaluated on the basis of a one-sided exact binomial test with a null DC rate of 15% versus 35% (power, 0.84; α, .10). Secondary end points were objective response (OR), progression-free survival, overall survival, duration of response, duration of stable disease, and safety., Results: Twenty-eight patients with 12 tumor types with BRAF alterations were enrolled from June 2016 to June 2021. All patients were evaluable for efficacy. Two patients with PR and four with SD16+ were observed for DC and OR rates of 21% (90% CI, 12 to 100) and 7% (95% CI, 1 to 24), respectively. The null hypothesis of 15% DC rate was not rejected ( P = .24). Eight patients had at least one grade 3 adverse event or serious adverse event at least possibly related to regorafenib., Conclusion: Regorafenib did not meet prespecified criteria to declare a signal of activity in patients with solid tumors with BRAF alterations.
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.